Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix in Psoriasis and Psoriatic Arthritis
2024-512881-32-00Phase 4Authorised
- Sponsor
- Justus Liebig University Giessen
- Start
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by Justus Liebig University Giessen. Primary endpoint: Increase in psoriasis or psoriatic arthritis activity within 12 weeks after first vaccination. Planned start Sep 2024; status: authorised.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2024-512881-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512881-32-00.